Iovance Biotherapeutics (IOVA) Stock Statistics & Valuation Metrics

Iovance Biotherapeutics has a market cap or net worth of $1.84B. The enterprise value is $1.32B.

Iovance Biotherapeutics has 446,502,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Iovance Biotherapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -51.52%.

The current PE Ratio of Iovance Biotherapeutics is ―. Iovance Biotherapeutics’s PEG ratio is 0.17.

In the last 12 months, Iovance Biotherapeutics had revenue of 263.50M and earned -390.98M in profits. Earnings per share was -1.09.

In the last 12 months, operating cash flow was -270.79M and capital expenditures -34.23M, giving a free cash flow of -305.02M billion.

Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Iovance Biotherapeutics upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Iovance Biotherapeutics as a current ratio of 3.20, with Debt / Equity ratio of 6.48%

In the past 12 months, Iovance Biotherapeutics has paid -2.07M in taxes.

Iovance Biotherapeutics EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -2.56.

Iovance Biotherapeutics has $313.44M in cash and marketable securities with $46.78M in debt, giving a net cash position of $266.67M billion.

Gross margin is 114.51%, with operating margin of -153.08%, and net profit margin of -148.38%.

The average price target for Iovance Biotherapeutics is $8.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy